Showing results (161-170 of 331) with videos related to

Sort By:
Pageof 34
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint InhibitorsFaisal Fa'ak, Nicolas Coudray, George Jour, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2020
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicityVickie R Shannon, Ronald Anderson, Ada Blidner, et al.
Oncoimmunology|June 7, 2018
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2Na Luo, Luigi Formisano, Paula I Gonzalez-Ericsson, et al.
Cancer|December 7, 2018
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapyKarim R Saab, Meghan J Mooradian, Daniel Y Wang, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disordersLauren J Brown, Alison Weppler, Prachi Bhave, et al.
Molecular Cancer|June 7, 2021
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeChi Yan, Nabil Saleh, Jinming Yang, et al.
Journal of the American College of Cardiology|September 28, 2019
Cardiovascular Toxicities Associated With IbrutinibJoe-Elie Salem, Ali Manouchehri, Marie Bretagne, et al.
Oncoimmunology|May 17, 2017
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profilingPeter J Siska, Romany A N Johnpulle, Alice Zhou, et al.
Oncotarget|June 19, 2015
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanomaKatherine E Hutchinson, Douglas B Johnson, Adam S Johnson, et al.
Pageof 34